199 related articles for article (PubMed ID: 16685513)
1. Stratification of medulloblastoma on the basis of histopathological grading.
Giangaspero F; Wellek S; Masuoka J; Gessi M; Kleihues P; Ohgaki H
Acta Neuropathol; 2006 Jul; 112(1):5-12. PubMed ID: 16685513
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.
Eberhart CG; Kepner JL; Goldthwaite PT; Kun LE; Duffner PK; Friedman HS; Strother DR; Burger PC
Cancer; 2002 Jan; 94(2):552-60. PubMed ID: 11900240
[TBL] [Abstract][Full Text] [Related]
3. Histopathologic grading of adult medulloblastomas.
Rodriguez FJ; Eberhart C; O'Neill BP; Slezak J; Burger PC; Goldthwaite P; Wu W; Giannini C
Cancer; 2007 Jun; 109(12):2557-65. PubMed ID: 17487854
[TBL] [Abstract][Full Text] [Related]
4. Microvessel density and vascular endothelial growth factor expression as predictors of childrens' survival from cerebellar medulloblastoma.
Tural S; Gercek A; Konya D; Ozgen S; Toplamoglu H; Ozek MM
J Clin Neurosci; 2009 Sep; 16(9):1199-202. PubMed ID: 19524442
[TBL] [Abstract][Full Text] [Related]
5. Biologic risk stratification of medulloblastoma: the real time is now.
Fisher PG; Burger PC; Eberhart CG
J Clin Oncol; 2004 Mar; 22(6):971-4. PubMed ID: 14970187
[No Abstract] [Full Text] [Related]
6. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
7. [Medulloblastoma in children. Prognostic incidence of vascular hyperplasia, coagulation necrosis and postoperative clinical state on survival].
Maire JP; Guérin J; Rivel J; San Galli F; Bernard C; Dautheribes M; Caudry M
Neurochirurgie; 1992; 38(2):80-8. PubMed ID: 1603234
[TBL] [Abstract][Full Text] [Related]
8. Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.
Min HS; Lee YJ; Park K; Cho BK; Park SH
Acta Neuropathol; 2006 Jul; 112(1):13-20. PubMed ID: 16691420
[TBL] [Abstract][Full Text] [Related]
9. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
Pizer BL; Clifford SC
Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
[TBL] [Abstract][Full Text] [Related]
10. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
Fattet S; Haberler C; Legoix P; Varlet P; Lellouch-Tubiana A; Lair S; Manie E; Raquin MA; Bours D; Carpentier S; Barillot E; Grill J; Doz F; Puget S; Janoueix-Lerosey I; Delattre O
J Pathol; 2009 May; 218(1):86-94. PubMed ID: 19197950
[TBL] [Abstract][Full Text] [Related]
11. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
[TBL] [Abstract][Full Text] [Related]
12. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.
Ellison DW; Onilude OE; Lindsey JC; Lusher ME; Weston CL; Taylor RE; Pearson AD; Clifford SC;
J Clin Oncol; 2005 Nov; 23(31):7951-7. PubMed ID: 16258095
[TBL] [Abstract][Full Text] [Related]
13. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
Haberler C; Slavc I; Czech T; Gelpi E; Heinzl H; Budka H; Urban C; Scarpatetti M; Ebetsberger-Dachs G; Schindler C; Jones N; Klein-Franke A; Maier H; Jauk B; Kiefer A; Hainfellner JA
Eur J Cancer; 2006 Nov; 42(17):2996-3003. PubMed ID: 16996732
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study.
Ozer E; Sarialioglu F; Cetingoz R; Yüceer N; Cakmakci H; Ozkal S; Olgun N; Uysal K; Corapcioglu F; Canda S
Pathol Res Pract; 2004; 200(7-8):501-9. PubMed ID: 15462497
[TBL] [Abstract][Full Text] [Related]
15. Medulloblastomas with favorable versus unfavorable histology: how many small blue cell tumor types are there in the brain?
Perry A
Adv Anat Pathol; 2002 Nov; 9(6):345-50. PubMed ID: 12409643
[TBL] [Abstract][Full Text] [Related]
16. c-myc overexpression causes anaplasia in medulloblastoma.
Stearns D; Chaudhry A; Abel TW; Burger PC; Dang CV; Eberhart CG
Cancer Res; 2006 Jan; 66(2):673-81. PubMed ID: 16423996
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 expression inversely correlates with tumour cell differentiation in medulloblastoma.
Schüller U; Schober F; Kretzschmar HA; Herms J
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):513-21. PubMed ID: 15488027
[TBL] [Abstract][Full Text] [Related]
18. [Risk stratification in medulloblastoma: screening for molecular markers].
Ebinger M; Senf L; Scheurlen W
Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669
[TBL] [Abstract][Full Text] [Related]
19. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
Rutkowski S; von Bueren A; von Hoff K; Hartmann W; Shalaby T; Deinlein F; Warmuth-Metz M; Soerensen N; Emser A; Bode U; Mittler U; Urban C; Benesch M; Kortmann RD; Schlegel PG; Kuehl J; Pietsch T; Grotzer M
Clin Cancer Res; 2007 May; 13(9):2651-7. PubMed ID: 17473196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
